News for Rakovina Therapeutics Inc. (RKV.V)

VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the 'Company” or 'Rakovina”) a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announced that, as an update to the previously announced warrant amendments, the Company intends to implement an early exercise warrant incentive program (the 'Incentive Program”) intended to encourage the exercise of up to 19,200,000 outstanding common share purchase warrants of the Company (the 'Eligible Warrants”) which were issued as part of a non-brokered private placement that closed in multiple tranches between June 26, 2024 and July 26, 2024.

Compounds developed through collaboration with Variational AI show targeted activity

VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC).

Award Recognition underscores the importance of AI-driven drug discovery

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to highlight the strength and scientific leadership of its established Scientific Advisory Board (SAB). Rakovina’s SAB is composed of internationally recognized experts in oncology, AI-driven drug development, and precision medicine. The board plays a vital role in shaping the company’s research strategy, pipeline advancement, and translational development initiatives.

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the 'Company”) announces that it will apply to the TSX Venture Exchange (the 'Exchange”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.

**media[648042]**

**media[639815]**

**media[627625]**

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing inno

**media[564375]**

Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered Collaborations

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer the…

**media[528418]**

VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (

**media[527271]**

**media[506853]**

VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the development of n…